Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

The growing global burden of neuropsychiatric disorders is a critical driver for the treatment market. With over 9.1 million annual deaths attributed to neurological diseases and an additional 8 ...

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

A single dose of a synthetic psilocybin was found to improve symptoms in patients with treatment-resistant depression.

Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...

A second phase 3 trial, COMP006 (ClinicalTrials.gov Identifier: NCT05711940), is currently evaluating 2 administrations of COMP360 psilocybin in TRD patients, with 26-week data expected in the ...

An Iowa lawmaker who had pushed for the passage Gov. Kim Reynolds’ decision to veto a bill pertaining to the psychoactive ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a primary ...

In its third-quarter results update, Compass also caused jitters amongst its investors as it revealed that it will shift the data readout for phase 3 trials of the psilocybin-based COMP360 therapy ...

The NHS Business Services Authority (NHSBSA) has released its latest report, ‘Medicines Used in Mental Health’, covering the period October to December 2022 of the financial year (Q4) for five ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...